STOCK TITAN
  1. Home
  2. News
  3. GHSI

Guardion Health Sciences Inc - GHSI STOCK NEWS

Welcome to our dedicated news page for Guardion Health Sciences (Ticker: GHSI), a resource for investors and traders seeking the latest updates and insights on Guardion Health Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardion Health Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardion Health Sciences's position in the market.

News
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
Rhea-AI Summary
Guardion Health Sciences, Inc. (GHSI) reports a 12% increase in net revenues, reaching approximately $11.9 million for the year ended December 31, 2023. The Viactiv® product line contributed significantly to the revenue growth, accounting for 97.2% of total revenue. The company also saw a 19.3% increase in gross profit, with a gross margin of 44.0%. Operating expenses decreased by 55.7%, resulting in a net income of $158,033 for 2023. Recent developments include an agreement to sell Activ Nutritional, for $17.2 million and a potential dissolution of the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.
Rhea-AI Summary
Guardion Health Sciences, Inc. (Nasdaq: GHSI) has signed an equity purchase agreement to sell its Activ Nutritional, LLC subsidiary, which owns the Viactiv® brand and business, to Doctor’s Best Inc. for $17.2 million. The transaction is subject to stockholder approval and is expected to close by June 30, 2024. The Viactiv® brand has shown 13% year-on-year topline revenue growth for the nine months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.72%
Tags
none
-
News
Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023
Rhea-AI Summary
Guardion Health Sciences, Inc. (Nasdaq: GHSI) announced net revenues of $3.3 million for the three months ended September 30, 2023, a 27% increase over the same period in 2022. The increase was primarily driven by sales growth of the Viactiv® product line. The Company also provided a corporate update to stockholders, including financial highlights and significant events. Jan Hall, the President and CEO, expressed satisfaction with the progress, highlighting strong topline growth, improved operating margins, and reduced cash burn. The Company is also continuing a strategic review process with Alantra, LLC to evaluate opportunities to maximize stockholder value in the near-term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
earnings
News
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
earnings
-
News
Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
management
-
News
Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
earnings
News
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
earnings
-
News
Guardion Health Sciences Hires Alantra, LLC as its Financial Advisor to Explore Strategic Alternatives to Maximize Stockholder Value
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
management
-
News
Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
none
News
Guardion Health Sciences, Inc. Announces 1-for-50 Reverse Stock Split Effective on Pre-Market Opening on January 9, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock GHSI logo
Guardion Health Sciences Inc

Nasdaq:GHSI

GHSI Rankings

#5368 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

GHSI Stock Data

10.14M
1.05M
22.3%
16.45%
10.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About GHSI

by applying the latest science, technology and research, guardion health sciences (ghs) has positioned itself to address the escalating demand for solutions that promise to improve life-diminishing health problems facing the aging baby boomer generation. guardion health sciences is dedicated to applying a scientific discipline and pharmaceutical approach to the development of safe, standardized and effective condition specific solutions. using the individual and collective knowledge of the members of our science advisory board, we will advise healthcare professionals and the public on the importance of medical foods and nutrition to achieve overall good health. the company’s first medical food, lumega-z, is scientifically formulated to restore and maintain the macular protective pigment. a depleted macular pigment is a known contributor to amd. though lumega-z was created with the amd epidemic in mind, its ingredients are also thought to be beneficial for other types of eye disease (i.